Serum 25-hydroxyvitamin D does not correlate with pancreatic status, FEV1, BMI, IgG nor prescribed doses of oral supplementation in patients with cystic fibrosis.
(2017) ECFS — Location: Seville (2017)
Files
No attached file found for this publication.
Details
- Authors
- Abstract
- Background: Maintaining serum 25-hydroxyvitamin D (25-OHD) ≥30 ng/ mL is recommended for all individuals with CF. In the general population, as many as 40% of European individuals might be deficient in vitamin D (25 OH-D < 20 ng/mL), with a nadir (>60%) in late winter/early spring. Objectives: 1) To investigate the relationship between 25-OHD and pancreatic status, FEV1, BMI and IgG 2) To look at prescribed supplementation and 25-OH-D levels in patients sampled both during the extended winter (Oct-March: EW) and summer (April-Nov: ES) periods. Methods: Retrospective chart review of patients seen over the past 2 years fulfilling the following criteria: (1) classical CF without lung transplant (2) regular follow-up for >3 months) (3) full set of anthropometric, spirometric (6y+), and biological data (25-OHD, IgG) obtained on the same day. For patients with 25-OHD levels sampled at least 3 months apart during both EW and ES, average daily dose of oral vitamin D supplementation over the 10 preceding weeks was calculated. Results: 167 out of 208 patients were eligible (M: 52.4%, PS: 16.8%, ≥18 y: 54.5%). No relationship was found between 25OH-D and pancreatic status, FEV1 (% pr), IgG level (normalized for age) or BMI (z-score). 25OH-D level was ≥ 30 ng/mL in 88 patients (52.7%), 20–29 ng/mL in 51 (30.5%). Normal levels were more often reached in children (61.8%) than in adults (45%) (p < 0.05). In 96 patients sampled during EW and ES, median 25OH-D level was 12% higher in ES despite a 18% lower supplementation. For neither period was observed a significant positive relationship between 25OH-D level and daily dose of oral vitamin D supplementation. Conclusion: Though vitamin D formulations and degree of malabsorption can play a role, adherence might be the key limiting factor to reach optimal 25OH-D levels in many patients with CF.
- Affiliations
Citations
Beckers, M., Gohy, S., Goubau, C., & Lebecque, P. (2017). Serum 25-hydroxyvitamin D does not correlate with pancreatic status, FEV1, BMI, IgG nor prescribed doses of oral supplementation in patients with cystic fibrosis. Journal of Cystic Fibrosis, 16(S142), S142. https://hdl.handle.net/2078.5/238674 (Original work published 2017)